{"id":19878,"date":"2024-12-26T14:31:37","date_gmt":"2024-12-26T06:31:37","guid":{"rendered":"https:\/\/flcube.com\/?p=19878"},"modified":"2024-12-26T14:31:40","modified_gmt":"2024-12-26T06:31:40","slug":"sichuan-biokins-bl-m08d1-and-cspcs-sys6010-eye-breakthrough-therapy-designations-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19878","title":{"rendered":"Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China"},"content":{"rendered":"\n

The China\u2019s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical Co., Ltd\u2019s (SHA: 688506<\/a>) BL-M08D1 and CSPC Pharmaceutical Group Ltd\u2019s (HKG: 1093<\/a>) SYS6010 are on track to obtain Breakthrough Therapy Designations (BTDs) from the agency. These designations are for the treatment of recurrent small cell lung cancer patients who have failed previous platinum-based chemotherapy and anti-PD-1\/PD-L1 monoclonal antibody treatment, and EGFR mutant advanced non-small cell lung cancer (NSCLC) that has failed treatment with EGFR-TKI and platinum-based chemotherapy, respectively.<\/p>\n\n\n\n

BL-M08D1: An Innovative ADC Targeting EGFR and HER3<\/strong>
BL-M08D1, an in-house developed antibody drug conjugate (ADC) targeting EGFR and HER3, was out-licensed to US major Bristol-Myers Squibb (BMS; NYSE: BMY) at the end of 2023 in a deal worth USD 8.4 billion. This drug has previously obtained four BTD statuses in China, involving NSCLC, nasopharyngeal carcinoma, and esophageal squamous cell carcinoma, highlighting its potential impact on various cancer treatments.<\/p>\n\n\n\n

SYS6010: A Promising ADC with Global Patent Protection<\/strong>
SYS6010 is also an ADC product that has demonstrated good anti-tumor activities in multiple cancers in pre-clinical studies. The drug has been filed for patent protection both domestically and internationally, indicating the company’s commitment to securing intellectual property rights and expanding its global reach.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The China\u2019s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical…<\/p>\n","protected":false},"author":1,"featured_media":19879,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,34,171,855,857],"class_list":["post-19878","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-breakthrough-therapy","tag-cspc-pharmaceutical","tag-hkg-1093","tag-sha-688506"],"yoast_head":"\nSichuan Biokin's BL-M08D1 and CSPC's SYS6010 Eye Breakthrough Therapy Designations in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The China\u2019s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical Co., Ltd\u2019s (SHA: 688506) BL-M08D1 and CSPC Pharmaceutical Group Ltd\u2019s (HKG: 1093) SYS6010 are on track to obtain Breakthrough Therapy Designations (BTDs) from the agency. These designations are for the treatment of recurrent small cell lung cancer patients who have failed previous platinum-based chemotherapy and anti-PD-1\/PD-L1 monoclonal antibody treatment, and EGFR mutant advanced non-small cell lung cancer (NSCLC) that has failed treatment with EGFR-TKI and platinum-based chemotherapy, respectively.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19878\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin's BL-M08D1 and CSPC's SYS6010 Eye Breakthrough Therapy Designations in China\" \/>\n<meta property=\"og:description\" content=\"The China\u2019s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical Co., Ltd\u2019s (SHA: 688506) BL-M08D1 and CSPC Pharmaceutical Group Ltd\u2019s (HKG: 1093) SYS6010 are on track to obtain Breakthrough Therapy Designations (BTDs) from the agency. These designations are for the treatment of recurrent small cell lung cancer patients who have failed previous platinum-based chemotherapy and anti-PD-1\/PD-L1 monoclonal antibody treatment, and EGFR mutant advanced non-small cell lung cancer (NSCLC) that has failed treatment with EGFR-TKI and platinum-based chemotherapy, respectively.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19878\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-26T06:31:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-26T06:31:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122606.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19878#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19878\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China\",\"datePublished\":\"2024-12-26T06:31:37+00:00\",\"dateModified\":\"2024-12-26T06:31:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19878\"},\"wordCount\":227,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19878#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122606.png\",\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Breakthrough therapy\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19878#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19878\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19878\",\"name\":\"Sichuan Biokin's BL-M08D1 and CSPC's SYS6010 Eye Breakthrough Therapy Designations in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19878#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19878#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122606.png\",\"datePublished\":\"2024-12-26T06:31:37+00:00\",\"dateModified\":\"2024-12-26T06:31:40+00:00\",\"description\":\"The China\u2019s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical Co., Ltd\u2019s (SHA: 688506) BL-M08D1 and CSPC Pharmaceutical Group Ltd\u2019s (HKG: 1093) SYS6010 are on track to obtain Breakthrough Therapy Designations (BTDs) from the agency. These designations are for the treatment of recurrent small cell lung cancer patients who have failed previous platinum-based chemotherapy and anti-PD-1\\\/PD-L1 monoclonal antibody treatment, and EGFR mutant advanced non-small cell lung cancer (NSCLC) that has failed treatment with EGFR-TKI and platinum-based chemotherapy, respectively.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19878#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19878\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19878#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122606.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122606.png\",\"width\":1080,\"height\":720,\"caption\":\"Sichuan Biokin's BL-M08D1 and CSPC's SYS6010 Eye Breakthrough Therapy Designations in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19878#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin's BL-M08D1 and CSPC's SYS6010 Eye Breakthrough Therapy Designations in China - Insight, China's Pharmaceutical Industry","description":"The China\u2019s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical Co., Ltd\u2019s (SHA: 688506) BL-M08D1 and CSPC Pharmaceutical Group Ltd\u2019s (HKG: 1093) SYS6010 are on track to obtain Breakthrough Therapy Designations (BTDs) from the agency. These designations are for the treatment of recurrent small cell lung cancer patients who have failed previous platinum-based chemotherapy and anti-PD-1\/PD-L1 monoclonal antibody treatment, and EGFR mutant advanced non-small cell lung cancer (NSCLC) that has failed treatment with EGFR-TKI and platinum-based chemotherapy, respectively.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19878","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin's BL-M08D1 and CSPC's SYS6010 Eye Breakthrough Therapy Designations in China","og_description":"The China\u2019s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical Co., Ltd\u2019s (SHA: 688506) BL-M08D1 and CSPC Pharmaceutical Group Ltd\u2019s (HKG: 1093) SYS6010 are on track to obtain Breakthrough Therapy Designations (BTDs) from the agency. These designations are for the treatment of recurrent small cell lung cancer patients who have failed previous platinum-based chemotherapy and anti-PD-1\/PD-L1 monoclonal antibody treatment, and EGFR mutant advanced non-small cell lung cancer (NSCLC) that has failed treatment with EGFR-TKI and platinum-based chemotherapy, respectively.","og_url":"https:\/\/flcube.com\/?p=19878","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-26T06:31:37+00:00","article_modified_time":"2024-12-26T06:31:40+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122606.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19878#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19878"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China","datePublished":"2024-12-26T06:31:37+00:00","dateModified":"2024-12-26T06:31:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19878"},"wordCount":227,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=19878#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122606.png","keywords":["ADC \/ XDC","Biokin Pharmaceutical","Breakthrough therapy","CSPC Pharmaceutical","HKG: 1093","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19878#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19878","url":"https:\/\/flcube.com\/?p=19878","name":"Sichuan Biokin's BL-M08D1 and CSPC's SYS6010 Eye Breakthrough Therapy Designations in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=19878#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=19878#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122606.png","datePublished":"2024-12-26T06:31:37+00:00","dateModified":"2024-12-26T06:31:40+00:00","description":"The China\u2019s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical Co., Ltd\u2019s (SHA: 688506) BL-M08D1 and CSPC Pharmaceutical Group Ltd\u2019s (HKG: 1093) SYS6010 are on track to obtain Breakthrough Therapy Designations (BTDs) from the agency. These designations are for the treatment of recurrent small cell lung cancer patients who have failed previous platinum-based chemotherapy and anti-PD-1\/PD-L1 monoclonal antibody treatment, and EGFR mutant advanced non-small cell lung cancer (NSCLC) that has failed treatment with EGFR-TKI and platinum-based chemotherapy, respectively.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19878#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19878"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=19878#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122606.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122606.png","width":1080,"height":720,"caption":"Sichuan Biokin's BL-M08D1 and CSPC's SYS6010 Eye Breakthrough Therapy Designations in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19878#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122606.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19878"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19878\/revisions"}],"predecessor-version":[{"id":19880,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19878\/revisions\/19880"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/19879"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}